Indivior Pays Out Over Blocking US Suboxone Rivals

Company Settles For $10m Over Frustrating Buprenorphine/Naloxone Generics

 
• By Dave Wallace

Indivior has agreed to pay $10m to settle antitrust charges by the US Federal Trade Commission over its Suboxone brand.

FTC
Indivior has struck a $10m deal with the FTC • Source: Shutterstock

More from Regulation

More from Policy & Regulation